Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bioterrorism -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (839)	10/11/2005 7:09:55 AM
From: Icebrg	Respond to of 891

>>PA is the most common target of the latest approach to fighting anthrax infection, said Young, who is a co-founder of PharmAthene Inc., another company developing an anthrax treatment, PharmAthene and Medarex Inc., another biotech, are developing Valortim, a drug that binds PA to a second receptor, which prevents if from ushering edema factor and lethal factor into the cell.>> More on the Valortim mAb from PR issued by Medarex today. Message 21781538 Erik